(Q46849239)

English

A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

phase II clinical trial

0 references

0 references

19

object named as

Pierre Fenaux

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

author name string

Didier Bouscary

1

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Laurence Legros

2

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Micheline Tulliez

3

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Stéphanie Dubois

4

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Béatrice Mahe

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Odile Beyne-Rauzy

6

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Marie C Quarre

7

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Dominique Vassilief

8

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Bruno Varet

9

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Achille Aouba

10

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Martine Gardembas

11

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Stéphane Giraudier

12

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Agnès Guerci

13

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Philippe Rousselot

14

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Fanny Gaillard

15

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Anne Moreau

16

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Marie C Rousselet

17

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Norbert Ifrah

18

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

François Dreyfus

20

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

Groupe Français des Myélodysplasies (GFM)

21

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

language of work or name

0 references

publication date

1 December 2005

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

131

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

5

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

609-618

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

The evolution of thalidomide and its IMiD derivatives as anticancer agents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Angiogenesis in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Thalidomide for the treatment of patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05817.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2005.05817.X

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 December 2017

http://europepmc.org/abstract/MED/16351636

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46849239&oldid=2134691895"